InnovAge Holding Past Earnings Performance
Past criteria checks 0/6
InnovAge Holding's earnings have been declining at an average annual rate of -22.4%, while the Healthcare industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 4.5% per year.
Key information
-22.4%
Earnings growth rate
-20.3%
EPS growth rate
| Healthcare Industry Growth | 8.5% |
| Revenue growth rate | 4.5% |
| Return on equity | -6.2% |
| Net Margin | -2.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Aren't Entirely Convinced By InnovAge Holding Corp.'s (NASDAQ:INNV) Revenues
Nov 07
Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
Aug 20InnovAge Holding Corp.'s (NASDAQ:INNV) Shares Leap 30% Yet They're Still Not Telling The Full Story
Jun 28Sentiment Still Eluding InnovAge Holding Corp. (NASDAQ:INNV)
May 07InnovAge Holding (NASDAQ:INNV) Has Debt But No Earnings; Should You Worry?
Mar 15Market Still Lacking Some Conviction On InnovAge Holding Corp. (NASDAQ:INNV)
Jan 06InnovAge Holding Corp.'s (NASDAQ:INNV) Intrinsic Value Is Potentially 73% Above Its Share Price
Aug 10Cautious Investors Not Rewarding InnovAge Holding Corp.'s (NASDAQ:INNV) Performance Completely
Jun 08InnovAge GAAP EPS of -$0.09 misses by $0.06, revenue of $172.86M misses by $1.11M
Sep 13InnovAge names Richard Feifer as chief medical officer
Aug 17InnovAge Holding (NASDAQ:INNV) Could Be Struggling To Allocate Capital
Jul 27Earnings Miss: InnovAge Holding Corp. Missed EPS And Analysts Are Revising Their Forecasts
May 12Here's What's Concerning About InnovAge Holding's (NASDAQ:INNV) Returns On Capital
Apr 14Is There An Opportunity With InnovAge Holding Corp.'s (NASDAQ:INNV) 30% Undervaluation?
Mar 24InnovAge Pursues Compliance As Precursor To Post-Pandemic Growth
Mar 19InnovAge Holding's (NASDAQ:INNV) Robust Earnings Are Supported By Other Strong Factors
Nov 16Are Investors Undervaluing InnovAge Holding Corp. (NASDAQ:INNV) By 48%?
Jul 28Revenue & Expenses Breakdown
How InnovAge Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 787 | -16 | 547 | 0 |
| 30 Jun 24 | 764 | -21 | 539 | 0 |
| 31 Mar 24 | 741 | -31 | 530 | 0 |
| 31 Dec 23 | 721 | -32 | 519 | 0 |
| 30 Sep 23 | 699 | -38 | 513 | 0 |
| 30 Jun 23 | 688 | -41 | 510 | 0 |
| 31 Mar 23 | 684 | -42 | 511 | 0 |
| 31 Dec 22 | 689 | -38 | 518 | 0 |
| 30 Sep 22 | 697 | -27 | 518 | 0 |
| 30 Jun 22 | 699 | -7 | 505 | 0 |
| 31 Mar 22 | 697 | 13 | 493 | 0 |
| 31 Dec 21 | 676 | 5 | 463 | 0 |
| 30 Sep 21 | 658 | 13 | 432 | 0 |
| 30 Jun 21 | 638 | -44 | 405 | 0 |
| 31 Mar 21 | 619 | -38 | 375 | 0 |
| 31 Dec 20 | 607 | -20 | 365 | 0 |
| 30 Sep 20 | 585 | -26 | 355 | 0 |
| 30 Jun 20 | 567 | 26 | 350 | 0 |
| 30 Jun 19 | 466 | 20 | 287 | 0 |
Quality Earnings: INNV is currently unprofitable.
Growing Profit Margin: INNV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INNV is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare INNV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INNV is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.4%).
Return on Equity
High ROE: INNV has a negative Return on Equity (-6.18%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InnovAge Holding Corp. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Steven Valiquette | Barclays |
| Sarah James | Barclays |